The latest reporting is crystal clear: Trump’s GLOBE drug pricing demo is a joke. Trump thought we wouldn’t read the fine print. He thought we wouldn’t piece together that his shady backroom deals with big drug companies undermine these demos, leaving all but three drug companies exempt from price reductions. Reporting from Axios and the Washington Post exposes how the projected savings of this drug pricing model have plummeted by 96% —- from $11.9 billion to a measly $440 million —- basically guaranteeing that most seniors will not see “most-favored-nation pricing” on their prescription drugs. Once again, Trump stands on the ruins of another broken promise, choosing to protect corporate profits over the health of seniors and working families.
Trump’s Shell of a Plan Fails to Deliver Lower Prices for Seniors
Axios: The Trump Administration’s Shrinking Medicare Drug Price Experiment
The Washington Post: Health Brief: Drugmakers Unscathed by Trump’s Drug Price Plan
The Hill: Medicare De-fangs New Drug Pricing Model
The Wall Street Journal: Trump Administration Finalizes Plan to Lower Drug Prices in Medicare
Endpoints News: CMS Finalizes Globe Rule as Projected Medicare Savings Fall From $11.9B to $440M
STAT: Trump’s Watered-Down Medicare Drug Pricing Rule Saves 96% Less Than Initial Proposal
Reuters: Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions